A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

NCT04398485 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions

DRUG: ION251

Sponsor

Ionis Pharmaceuticals, Inc.